Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Less invasive surgery for cervical cancer put to the test

NCT ID NCT06836869

Disease control Sponsor: Peking Union Medical College Hospital Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study compares a newer, less invasive laparoscopic hysterectomy (with special tumor-free techniques) to the standard open abdominal surgery for stage IB2 cervical cancer. About 524 women will be randomly assigned to one of the two surgeries. The main goal is to see if the laparoscopic approach is as effective at preventing cancer recurrence over 4.5 years, while also being safer.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Laparoscopic radical hysterectomy with modified tumor-free techniques
What this could lead to
If successful, this could offer a less invasive surgical option for stage IB2 cervical cancer with similar effectiveness and fewer complications.
What could go wrong
This is a non-inferiority trial, so the laparoscopic approach may prove no better than the standard. Results may not apply to other cancer stages or types.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 524 people

The number the study aims to enrol. It can still change while the study runs.

Started

Feb 2025

Expected to finish

Jul 2032

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 65 years

Sex

Female participants only

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

1. Inclusion Criteria: 1.1 Females aged 18 to 65 years old. 1.2 Histologically confirmed primary cervical squamous cell carcinoma, adenocarcinoma, or adenosquamous carcinoma. 1.3 FIGO 2018 stage IB2. 1.4 The maximum diameter of the cervical lesion measured by MRI is \>2 cm and ≤4 cm. For those with MRI contraindications, PET/CT, CT, or ultrasound can be used as alternatives. 1.5 Scheduled to receive type C (Q - M classification) radical hysterectomy. 1.6 Eastern Cooperative Oncology Group (ECOG) performance status score of 0 or 1. 1.7 Willing to participate in this trial and sign the informed consent form. 1.8 Able to cooperate and complete follow - up and relevant examinations. 1.9 For pre - menopausal women, a negative pregnancy test within 30 days before surgery. 1.10 Laboratory test indicators of vital organs meet the standards 2. Exclusion Criteria: 2.1 Special pathological types (gastric - type adenocarcinoma, neuroendocrine carcinoma, clear cell carcinoma, carcinosarcoma, etc.). 2.2 Imaging examinations suggest pelvic or para - aortic lymph node metastasis (MRI or CT shows a short - axis diameter of ≥1.5 cm, or SUV ≥2.5), or histopathology indicates lymph node metastasis. 2.3 History of pelvic and abdominal radiotherapy. 2.4 History of neoadjuvant chemotherapy. 2.5 Uterus larger than that at 10 weeks of pregnancy. 2.6 Contraindications for surgery and anesthesia (such as severe medical comorbidities). 2.7 Patients who cannot tolerate the Trendelenburg position. 2.8 Patients who cannot cooperate with treatment and follow - up. 2.9 Pregnant patients. 2.10 History of other malignancies, except for those who have been cancer - free for more than 3 years with no current evidence of tumor recurrence.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Cervical cancer stage IB2 are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

cervical cancer Uterine Cervical Neoplasms

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Cervical cancer stage IB2

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    17 sites. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Affiliated Hospital of North Sichuan Medical College

    RECRUITING

    Nanchong, Sichuan, 637000, China

  • Affiliated Hospital of Shanxi University of Traditional Chinese Medicine

    RECRUITING

    Xianyang, Shanxi, 712000, China

  • Cangzhou Central Hospital

    RECRUITING

    Cangzhou, Hebei, 061000, China

  • Hunan Provincial Maternal and Child Health Care Hospital

    RECRUITING

    Changsha, Hunan, 410000, China

  • Obstetrics & Gynecology Hospital of Fudan University

    RECRUITING

    Shanghai, China

  • Peking Union Medical College Hospital

    RECRUITING

    Beijing, 100079, China

  • Renji Hospital Affiliated to The Shanghai Jiao Tong University Medical School

    RECRUITING

    Shanghai, Shanghai Municipality, 200001, China

  • Sichuan Cancer Hospital and Institute

    RECRUITING

    Chengdu, China

  • Southwest Hospital

    RECRUITING

    Chongqing, China

  • Sun Yat-sen Memorial Hospital, Sun Yat-sen University

    RECRUITING

    Guangzhou, Guangdong, 510120, China

  • The First Hospital of Lanzhou University

    NOT_YET_RECRUITING

    Lanzhou, Gansu, 730000, China

  • The Fourth Hospital of Hebei Medical University

    RECRUITING

    Shijiazhuang, Hebei, 050011, China

  • The Fourth Military Medical University, Xijing Hospital

    RECRUITING

    Xi’an, Shanxi, 710032, China

  • The Second Hospital of Jilin University

    RECRUITING

    Changchun, Jilin, 130041, China

  • Tianjin Central Hospital of Gynecology Obstetrics

    RECRUITING

    Tianjin, China

  • Tongji Medical College

    RECRUITING

    Wuhan, China

  • Zhejiang cancer hospital

    RECRUITING

    Hangzhou, Zhejiang, 310022, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.